Cargando…

Preclinical safety and efficacy of a new recombinant FIX drug product for treatment of hemophilia B

Baxter has developed a new recombinant factor IX (rFIX) drug product (BAX326) for treating patients with hemophilia B, or congenital FIX deficiency. An extensive preclinical program evaluated the pharmacokinetics, efficacy, and safety of BAX326 in different species. The efficacy of BAX326 was tested...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dietrich, Barbara, Schiviz, Alexandra, Hoellriegl, Werner, Horling, Frank, Benamara, Karima, Rottensteiner, Hanspeter, Turecek, Peter L., Schwarz, Hans Peter, Scheiflinger, Friedrich, Muchitsch, Eva-Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Japan 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091414/ https://www.ncbi.nlm.nih.gov/pubmed/24061775 http://dx.doi.org/10.1007/s12185-013-1448-z

Ejemplares similares

Development of an In Vitro Biopotency Assay for an AAV8 Hemophilia B Gene Therapy Vector Suitable for Clinical Product Release
por: Lengler, Johannes, et al.
Publicado: (2020)

Temperature‐dependent irreversible conformational change of recombinant ADAMTS13 upon metal ion chelation
por: Rottensteiner, Hanspeter, et al.
Publicado: (2019)

Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease
por: Rossato, Paolo, et al.
Publicado: (2022)

Expression of recombinant human coagulation factors VII (rFVII) and IX (rFIX) in various cell types, glycosylation analysis, and pharmacokinetic comparison
por: Böhm, Ernst, et al.
Publicado: (2011)

Minimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy Efficiency
por: Cao, Wenjing, et al.
Publicado: (2020)

Development of Methods for the Selective Measurement of the Single Amino Acid Exchange Variant Coagulation Factor IX Padua
por: Weber, Alfred, et al.
Publicado: (2018)

Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias
por: Mancuso, Maria Elisa, et al.
Publicado: (2014)

Identification of cysteine thiol‐based linkages in ADAMTS13 in support of a non‐proteolytic regulation of von Willebrand factor
por: Rottensteiner, Hanspeter, et al.
Publicado: (2019)

Absence of exaggerated pharmacology by recombinant ADAMTS13 in the rat and monkey
por: Rossato, Paolo, et al.
Publicado: (2022)

How Full-Length FVIII Benefits from Its Heterogeneity – Insights into the Role of the B-Domain
por: Anzengruber, Julia, et al.
Publicado: (2019)

Modulation of the liver immune microenvironment by the adeno-associated virus serotype 8 gene therapy vector
por: Carestia, Agostina, et al.
Publicado: (2020)

Albumin-Fusion Recombinant FIX in the Management of People with Hemophilia B: An Evidence-Based Review
por: Pasca, Samantha, et al.
Publicado: (2022)

The Molecular Basis of FIX Deficiency in Hemophilia B
por: Shen, Guomin, et al.
Publicado: (2022)

Coagulation phenotype of wild-type mice on different genetic backgrounds
por: Kopić, Alexandra, et al.
Publicado: (2018)

Major cardiac surgery with recombinant FIX Fc fusion protein replacement in hemophilia B: a case report
por: Bohn, Jan-Paul, et al.
Publicado: (2022)

Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors
por: Kruzik, Anita, et al.
Publicado: (2019)

Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors
por: Négrier, Claude, et al.
Publicado: (2022)

Recombinant FVIII: the milestone of modern hemophilia treatment
por: Mannucci, Pier Mannuccio
Publicado: (2023)

Polyethylene glycol 20 kDa-induced vacuolation does not impair phagocytic function of human monocyte-derived macrophages
por: Schoenbrunn, Anne, et al.
Publicado: (2022)

Treatment of hemophilia B: focus on recombinant factor IX
por: Franchini, Massimo, et al.
Publicado: (2013)

GlycoPEGylated recombinant factor IX for hemophilia B in context
por: Santagostino, Elena, et al.
Publicado: (2018)

Differences in N-glycosylation of recombinant human coagulation factor VII derived from BHK, CHO, and HEK293 cells
por: Böhm, Ernst, et al.
Publicado: (2015)

Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa
por: Lissitchkov, Toshko, et al.
Publicado: (2023)

Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia
por: Thorat, Teja, et al.
Publicado: (2018)

Biodistribution of recombinant factor IX, extended half-life recombinant factor IX Fc fusion protein, and glycoPEGylated recombinant factor IX in hemophilia B mice
por: van der Flier, Arjan, et al.
Publicado: (2023)

Recombinant factor VIII in the management of hemophilia A: current use and future promise
por: Powell, Jerry S
Publicado: (2009)

Potential role of a new PEGylated recombinant factor VIII for hemophilia A
por: Wynn, Tung Thanh, et al.
Publicado: (2016)

Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients
por: Abolghasemi, Hassan, et al.
Publicado: (2018)

Avoiding unscheduled transcription in shared promoters: Saccharomyces cerevisiae Sum1p represses the divergent gene pair SPS18-SPS19 through a midsporulation element (MSE)
por: Gurvitz, Aner, et al.
Publicado: (2009)

A novel supplemental approach to capturing post-marketing safety information on recombinant factor VIIa in acquired hemophilia: the Acquired Hemophilia Surveillance project
por: Lentz, Steven R, et al.
Publicado: (2014)

Recombinant and Chimeric Disintegrins in Preclinical Research
por: David, Victor, et al.
Publicado: (2018)

Preclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia A
por: Elkouby, Liron, et al.
Publicado: (2021)

Liver lobe-specific hydrodynamic gene delivery to baboons: A preclinical trial for hemophilia gene therapy
por: Kamimura, Kenya, et al.
Publicado: (2023)

Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitors
por: Chuansumrit, Ampaiwan, et al.
Publicado: (2010)

Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B
por: Djambas Khayat, Claudia
Publicado: (2016)

Protein C in murine neonatal sepsis
por: Muchitsch, E, et al.
Publicado: (2005)

Practice of Iranian Adolescents with Hemophilia in Prevention of Complications of Hemophilia
por: Valizadeh, Leila, et al.
Publicado: (2015)

Preclinical trauma studies of recombinant factor VIIa
por: Schreiber, Martin A, et al.
Publicado: (2005)

Randomized, Controlled Comparison of Advanced Hemostatic Pads in Hepatic Surgical Models
por: Lewis, Kevin M., et al.
Publicado: (2014)

Use of recombinant activated factor VII for acute bleeding episodes in acquired hemophilia: final analysis from the Hemostasis and Thrombosis Research Society Registry acquired hemophilia study
por: Ma, Alice D., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ajn43t4031d8usmrbn2mfpfn18